search
Back to results

Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion

Primary Purpose

Cervical Disc Herniation, Cervical Degenerative Disc Disease, Cervical Spondylotic Myelopathy

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Methylprednisolone Acetate
Hemostatic Matrix Kit
Sponsored by
Hospital for Special Surgery, New York
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cervical Disc Herniation focused on measuring Anterior Cervical Discectomy and Fusion, Dysphagia, ACDF

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Any patient > 18 years undergoing a 2-4 level Anterior Cervical Discectomy and Fusion

Exclusion Criteria:

  • Patients undergoing revision surgery
  • Pediatric patients
  • Trauma patients with cervical spine fractures
  • Patients with cancer
  • Patients with active infection
  • Patients with a known allergy to Methylprednisolone Acetate
  • Patients who refuse to participate
  • Non English speakers

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Treatment

    Control

    Arm Description

    Procedure: Anterior Cervical Discectomy and Fusion. The treatment arm will receive 40 mg of Methylprednisolone Acetate delivered with a Hemostatic Matrix Kit prior to closure.

    Procedure: Anterior Cervical Discectomy and Fusion. The control group will receive only a Hemostatic Matrix Kit prior to closure.

    Outcomes

    Primary Outcome Measures

    Degree of Dysphagia Patients Experience (Burden)
    SWAL-QOL survey - Burden domain Score ranges between 0 and 100 (worst-best)
    Degree of Dysphagia Patients Experience (Eating Desire)
    SWAL-QOL survey - Eating desire domain Score ranges between 0 and 100 (worst-best)
    Degree of Dysphagia Patients Experience (Eating Duration)
    SWAL-QOL survey - Eating duration domain Score ranges between 0 and 100 (worst-best)
    Degree of Dysphagia Patients Experience (Food Selection)
    SWAL-QOL survey - Food Selection domain Score ranges between 0 and 100 (worst-best)
    Degree of Dysphagia Patients Experience (Communication)
    SWAL-QOL survey - Communication domain Score ranges between 0 and 100 (worst-best)
    Degree of Dysphagia Patients Experience (Fear Swallow)
    SWAL-QOL survey - Fear swallow domain Score ranges between 0 and 100 (worst-best)
    Degree of Dysphagia Patients Experience (Social)
    SWAL-QOL survey - Social domain Score ranges between 0 and 100 (worst-best)
    Degree of Dysphagia Patients Experience (Mental)
    SWAL-QOL survey - Mental domain Score ranges between 0 and 100 (worst-best)
    Degree of Dysphagia Patients Experience (Sleep)
    SWAL-QOL survey - Sleep domain Score ranges between 0 and 100 (worst-best)
    Degree of Dysphagia Patients Experience (Fatigue)
    SWAL-QOL survey - Fatigue domain Score ranges between 0 and 100 (worst-best)

    Secondary Outcome Measures

    Patient Reported Swallowing Difficulty Over 1 Year
    The Eating Assessment Tool (EAT-10) is used to screen for self-perceived oropharyngeal dysphagia (OD) in community-dwelling elders. A summated EAT-10 total score ranges from 0 to 40, with a score ≥ 3 indicative of OD. Modified Eat-10 : Eat-10 questionnaire without questions 1 ("My swallowing problem has caused me to lose weight") and 2 ("My swallowing problem interferes with my ability to go out for meals") to be applicable during hospitalization. Eat-10 interpretation: Score ranging from 0 to 40 (best-worst) each question response is 0-4, 0=no problem and 4=severe problem; score is a summation of each question's response Modified EAT-10 interpretation: Score ranging from 0 to 32 (best-worst) each question response is 0-4, 0=no problem and 4=severe problem; score is a summation of each question's response
    Patients' Bazaz Dysphagia Score - Liquid
    Bazaz dysphagia scale defines dysphagia as none, mild, moderate and severe, depending on patients' symptoms with solid and liquid foods.
    Patients' Bazaz Dysphagia Score - Solid
    Bazaz dysphagia scale defines dysphagia as none, mild, moderate and severe, depending on patients' symptoms with solid and liquid foods.
    Patients' Neck Disability
    Neck Disability Index (NDI) Range from 0 to 100 (best-worst)
    Patients' Pain Scores on the Visual Analog Scale - Neck Pain
    Visual Analog Scale (VAS) - Neck pain Range from 0 to 100 (best-worst)
    Patients' Pain Scores on the Visual Analog Scale - Left Arm Pain
    Visual Analog Scale (VAS) - Left arm pain Range from 0 to 100 (best-worst)
    Patients' Pain Scores on the Visual Analog Scale - Right Arm Pain
    Visual Analog Scale (VAS) - Right arm pain Range from 0 to 100 (best-worst)
    Change in Pre-vertebral Soft Tissue Swelling Over 1 Year
    We are unable to report this outcome measure because soft tissue swelling was not assessed. The PI deemed it would not be included for this study as there is not a clinical or research standard to do so, nor is there normative data over time to compare against. Thus, data were not collected.
    Fusion Rate
    Flex-Ex X-rays Bony bridging on a CT scan Obvious bony remodeling on lateral X-ray
    Adverse Event
    Adverse Event (AE) following surgical treatment. Adverse event were classified by severity based on the AO-ISSG criteria and treatment required: Mild: Observed, medication, consult, X-ray. Essentially any management that was quick and easy and could be done at bedside Moderate: ICU admission, re-intubation, complication that had a documented prolonged hospital stay, medical procedure (such as flexible endoscopy), re-presentation to ED Severe: Inpatient re-admission, return to OR for any reason, mortality, failed OR. AE were also categorize as Surgery-site related or unrelated adverse event. Finally, AE were also categorize as potentially related to steroid use (example: leukocytosis, pseudoarthrosis, or wound complications)

    Full Information

    First Posted
    August 27, 2015
    Last Updated
    June 16, 2023
    Sponsor
    Hospital for Special Surgery, New York
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02539394
    Brief Title
    Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion
    Official Title
    Do Intraoperative Topical Corticosteroids Aid in the Prevention of Postoperative Dysphagia Following Elective Anterior Cervical Discectomy and Fusion? A Randomized, Controlled, Double Blinded Clinical Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2023
    Overall Recruitment Status
    Completed
    Study Start Date
    August 2015 (undefined)
    Primary Completion Date
    November 12, 2020 (Actual)
    Study Completion Date
    November 12, 2021 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Hospital for Special Surgery, New York

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The purpose of this study is to determine what effect intraoperative topical steroids have on reducing swallowing difficulty following Anterior Cervical Discectomy and Fusion surgery.
    Detailed Description
    Background: Dysphagia is a serious post-operative concern in patients following anterior cervical surgery. Although many experts have acknowledged that dysphagia is often incompletely understood and defined, there is a significant amount of literature to support the significance of this clinical entity. This is the first randomized study to examine the use of topical steroids for the prevention of dysphagia postoperatively after anterior cervical discectomy and fusion. Study Design: This study is a single site, double blinded randomized control trial. All individuals undergoing 2-4 level ACDF that meet the inclusion criteria will be randomized to either: treatment arm or control arm. Both arms will undergo their planned surgeries and will receive the exact same procedure and standard of care as if they were not enrolled in a study. The only difference is that the treatment arm will receive 40 mg of Methylprednisolone Acetate delivered with one Hemostatic Matrix Kit injectable delivery vehicle prior to closure in the prevertebral soft tissues. The control group will receive only Hemostatic Matrix Kit prior to closure in the prevertebral soft tissues. Outcomes: Patients will be asked to fill out questionnaires that assess dysphagia, general swallowing difficulty, and how neck pain impacts their quality of life. Additionally Radiographic images will be obtained at set time points to evaluate soft tissue inflammation and bony fusion.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cervical Disc Herniation, Cervical Degenerative Disc Disease, Cervical Spondylotic Myelopathy, Dysphagia, Osteoarthritis of Cervical Spine
    Keywords
    Anterior Cervical Discectomy and Fusion, Dysphagia, ACDF

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigator
    Allocation
    Randomized
    Enrollment
    128 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Treatment
    Arm Type
    Experimental
    Arm Description
    Procedure: Anterior Cervical Discectomy and Fusion. The treatment arm will receive 40 mg of Methylprednisolone Acetate delivered with a Hemostatic Matrix Kit prior to closure.
    Arm Title
    Control
    Arm Type
    Placebo Comparator
    Arm Description
    Procedure: Anterior Cervical Discectomy and Fusion. The control group will receive only a Hemostatic Matrix Kit prior to closure.
    Intervention Type
    Drug
    Intervention Name(s)
    Methylprednisolone Acetate
    Other Intervention Name(s)
    Depo-Medrol
    Intervention Description
    Methylprednisolone Acetate is a corticosteroid known to reduce swelling and inflammation.
    Intervention Type
    Other
    Intervention Name(s)
    Hemostatic Matrix Kit
    Intervention Description
    Hemostatic Matrix Kits help prevent uncontrollable bleeding in a operative site during a procedure.
    Primary Outcome Measure Information:
    Title
    Degree of Dysphagia Patients Experience (Burden)
    Description
    SWAL-QOL survey - Burden domain Score ranges between 0 and 100 (worst-best)
    Time Frame
    Post-Op Day 1, Post-Op Day 2, Week 4-6, 3 Months, 6 Months, 12 Months
    Title
    Degree of Dysphagia Patients Experience (Eating Desire)
    Description
    SWAL-QOL survey - Eating desire domain Score ranges between 0 and 100 (worst-best)
    Time Frame
    Post-Op Day 1, Post-Op Day 2, Week 4-6, 3 Months, 6 Months, 12 Months
    Title
    Degree of Dysphagia Patients Experience (Eating Duration)
    Description
    SWAL-QOL survey - Eating duration domain Score ranges between 0 and 100 (worst-best)
    Time Frame
    Post-Op Day 1, Post-Op Day 2, Week 4-6, 3 Months, 6 Months, 12 Months
    Title
    Degree of Dysphagia Patients Experience (Food Selection)
    Description
    SWAL-QOL survey - Food Selection domain Score ranges between 0 and 100 (worst-best)
    Time Frame
    Post-Op Day 1, Post-Op Day 2, Week 4-6, 3 Months, 6 Months, 12 Months
    Title
    Degree of Dysphagia Patients Experience (Communication)
    Description
    SWAL-QOL survey - Communication domain Score ranges between 0 and 100 (worst-best)
    Time Frame
    Post-Op Day 1, Post-Op Day 2, Week 4-6, 3 Months, 6 Months, 12 Months
    Title
    Degree of Dysphagia Patients Experience (Fear Swallow)
    Description
    SWAL-QOL survey - Fear swallow domain Score ranges between 0 and 100 (worst-best)
    Time Frame
    Post-Op Day 1, Post-Op Day 2, Week 4-6, 3 Months, 6 Months, 12 Months
    Title
    Degree of Dysphagia Patients Experience (Social)
    Description
    SWAL-QOL survey - Social domain Score ranges between 0 and 100 (worst-best)
    Time Frame
    Post-Op Day 1, Post-Op Day 2, Week 4-6, 3 Months, 6 Months, 12 Months
    Title
    Degree of Dysphagia Patients Experience (Mental)
    Description
    SWAL-QOL survey - Mental domain Score ranges between 0 and 100 (worst-best)
    Time Frame
    Post-Op Day 1, Post-Op Day 2, Week 4-6, 3 Months, 6 Months, 12 Months
    Title
    Degree of Dysphagia Patients Experience (Sleep)
    Description
    SWAL-QOL survey - Sleep domain Score ranges between 0 and 100 (worst-best)
    Time Frame
    Post-Op Day 1, Post-Op Day 2, Week 4-6, 3 Months, 6 Months, 12 Months
    Title
    Degree of Dysphagia Patients Experience (Fatigue)
    Description
    SWAL-QOL survey - Fatigue domain Score ranges between 0 and 100 (worst-best)
    Time Frame
    Post-Op Day 1, Post-Op Day 2, Week 4-6, 3 Months, 6 Months, 12 Months
    Secondary Outcome Measure Information:
    Title
    Patient Reported Swallowing Difficulty Over 1 Year
    Description
    The Eating Assessment Tool (EAT-10) is used to screen for self-perceived oropharyngeal dysphagia (OD) in community-dwelling elders. A summated EAT-10 total score ranges from 0 to 40, with a score ≥ 3 indicative of OD. Modified Eat-10 : Eat-10 questionnaire without questions 1 ("My swallowing problem has caused me to lose weight") and 2 ("My swallowing problem interferes with my ability to go out for meals") to be applicable during hospitalization. Eat-10 interpretation: Score ranging from 0 to 40 (best-worst) each question response is 0-4, 0=no problem and 4=severe problem; score is a summation of each question's response Modified EAT-10 interpretation: Score ranging from 0 to 32 (best-worst) each question response is 0-4, 0=no problem and 4=severe problem; score is a summation of each question's response
    Time Frame
    Pre-Op, Post-Op Day 1, Post-Op Day 2, Week 4-6, 3 Months, 6 Months, 12 Months
    Title
    Patients' Bazaz Dysphagia Score - Liquid
    Description
    Bazaz dysphagia scale defines dysphagia as none, mild, moderate and severe, depending on patients' symptoms with solid and liquid foods.
    Time Frame
    Pre-Op, Post-Op Day 1, Post-Op Day 2, Week 4-6, 3 Months, 6 Months, 12 Months
    Title
    Patients' Bazaz Dysphagia Score - Solid
    Description
    Bazaz dysphagia scale defines dysphagia as none, mild, moderate and severe, depending on patients' symptoms with solid and liquid foods.
    Time Frame
    Pre-Op, Post-Op Day 1, Post-Op Day 2, Week 4-6, 3 Months, 6 Months, 12 Months
    Title
    Patients' Neck Disability
    Description
    Neck Disability Index (NDI) Range from 0 to 100 (best-worst)
    Time Frame
    Pre-Op, Week 4-6, 3 Months, 6 Months, 12 Months
    Title
    Patients' Pain Scores on the Visual Analog Scale - Neck Pain
    Description
    Visual Analog Scale (VAS) - Neck pain Range from 0 to 100 (best-worst)
    Time Frame
    Pre-Op, Post-Op Day 1, Post-Op Day 2, Week 4-6, 3 Months, 6 Months, 12 Months
    Title
    Patients' Pain Scores on the Visual Analog Scale - Left Arm Pain
    Description
    Visual Analog Scale (VAS) - Left arm pain Range from 0 to 100 (best-worst)
    Time Frame
    Pre-Op, Post-Op Day 1, Post-Op Day 2, Week 4-6, 3 Months, 6 Months, 12 Months
    Title
    Patients' Pain Scores on the Visual Analog Scale - Right Arm Pain
    Description
    Visual Analog Scale (VAS) - Right arm pain Range from 0 to 100 (best-worst)
    Time Frame
    Pre-Op, Post-Op Day 1, Post-Op Day 2, Week 4-6, 3 Months, 6 Months, 12 Months
    Title
    Change in Pre-vertebral Soft Tissue Swelling Over 1 Year
    Description
    We are unable to report this outcome measure because soft tissue swelling was not assessed. The PI deemed it would not be included for this study as there is not a clinical or research standard to do so, nor is there normative data over time to compare against. Thus, data were not collected.
    Time Frame
    Pre-Op, Post-Op Day 1, Week 4-6, 3 Months, 6 Months, 12 Months
    Title
    Fusion Rate
    Description
    Flex-Ex X-rays Bony bridging on a CT scan Obvious bony remodeling on lateral X-ray
    Time Frame
    12 Months
    Title
    Adverse Event
    Description
    Adverse Event (AE) following surgical treatment. Adverse event were classified by severity based on the AO-ISSG criteria and treatment required: Mild: Observed, medication, consult, X-ray. Essentially any management that was quick and easy and could be done at bedside Moderate: ICU admission, re-intubation, complication that had a documented prolonged hospital stay, medical procedure (such as flexible endoscopy), re-presentation to ED Severe: Inpatient re-admission, return to OR for any reason, mortality, failed OR. AE were also categorize as Surgery-site related or unrelated adverse event. Finally, AE were also categorize as potentially related to steroid use (example: leukocytosis, pseudoarthrosis, or wound complications)
    Time Frame
    12 month

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Any patient > 18 years undergoing a 2-4 level Anterior Cervical Discectomy and Fusion Exclusion Criteria: Patients undergoing revision surgery Pediatric patients Trauma patients with cervical spine fractures Patients with cancer Patients with active infection Patients with a known allergy to Methylprednisolone Acetate Patients who refuse to participate Non English speakers
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Todd Albert, MD
    Organizational Affiliation
    Hospital for Special Surgery, New York
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion

    We'll reach out to this number within 24 hrs